购物车

全部删除
您的购物车当前为空

前往下单页继续购物

TNFR1/CD120a/TNFRSF1A Protein, Human, Recombinant (His) V2

一键复制产品信息

产品编号 TMPY-01459U

TNFR1/CD120a/TNFRSF1A Protein, Human, Recombinant (His) V2 is expressed in HEK293 Cells. The accession number is P19438-1.

TNFR1/CD120a/TNFRSF1A Protein, Human, Recombinant (His) V2

一键复制产品信息

产品编号 TMPY-01459U

TNFR1/CD120a/TNFRSF1A Protein, Human, Recombinant (His) V2 is expressed in HEK293 Cells. The accession number is P19438-1.

规格	价格	库存	数量

大包装 & 定制

TargetMol 的所有产品仅用作科学研究或药证申报，不能被用于人体，我们不向个人提供产品和服务。请您遵守承诺用途，不得违反法律法规规定用于任何其他用途。

实验操作小课堂

常见问题解答

资源下载

重组蛋白用户指南

产品信息

生物活性	Immobilized Human TNFR1, His Tag at 0.5 μg/ml (100 μl/Well). Dose response curve for Biotinylated Human TNF alpha, His Tag with the EC50 of 16.5 ng/ml determined by ELISA.
产品描述	TNFR1/CD120a/TNFRSF1A Protein, Human, Recombinant (His) V2 is expressed in HEK293 Cells. The accession number is P19438-1.
种属	Human
表达系统	HEK293 Cells
标签	C-His
蛋白编号	P19438-1
别名	tumor necrosis factor receptor superfamily member 1A,TNF-R-I,TNFR60,TNF-R55,TNFR55,TNFR1-d2,TNFR1,TNF-R,TNFAR,TBP1,p60,p55-R,p55,MS5,FPF,CD120a
蛋白构建	Leu30-Thr211
蛋白纯度	> 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC
分子量	23.3 kDa (Predicted); 38-48 kDa (Due to glycosylation)
内毒素	< 1.0 EU/μg of the protein as determined by the LAL method.
蛋白性状	Lyophilized powder
缓冲液	Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
存储	Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.
运输方式	In general, Lyophilized powders are shipping with blue ice. Solutions are shipping with dry ice.
研究背景	Tumour necrosis factor alpha (TNF-α) is a pleiotropic cytokine with both injurious and protective functions, which are thought to diverge at the level of its two cell surface receptors, TNFR1 and TNFR2. In the setting of acute injury, selective inhibition of TNFR1 is predicted to attenuate the cell death and inflammation associated with TNF-α, while sparing or potentiating the protective effects of TNFR2 signalling.